25
Participants
Start Date
November 16, 2020
Primary Completion Date
March 29, 2023
Study Completion Date
May 19, 2023
Cemiplimab
Cemiplimab (350 mg) will be administered IV on day 1 of each cycle (21 day cycle) for up to 2 years.
Plerixafor
Plerixafor (80mcg/kg/hr) will be administered as a continuous IV infusion of the first 7 days of each cycle (21 day cycle) for up to 2 years.
Sidney Kimmel Comprehensive Cancer Center, Baltimore
Genzyme, a Sanofi Company
INDUSTRY
American Association for Cancer Research
OTHER
National Cancer Institute (NCI)
NIH
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
OTHER